Treatment Outcome of Newly Diagnosed Acute Promyelocytic Leukaemia by All-Trans Retinoic Acid followed by Arsenic Tri-Oxide

Haematology Journal of Bangladesh

View Publication Info
 
 
Field Value
 
Title Treatment Outcome of Newly Diagnosed Acute Promyelocytic Leukaemia by All-Trans Retinoic Acid followed by Arsenic Tri-Oxide
 
Creator Islam, AKM Mynul
Ali, Mohammad
Al Anis, Mohammad Abdullah
Aziz, Ahmad Monzurul
Siddika, Syeda Subrina
Haque, Salina
Chowdhury, Zulfia Zinat
Biswas, Akhil Ranjon
Ara, Tasneem
Rahman, Md. Mahabubur
Afrose, Salma
 
Subject all Trans Retinoic Acid
Acute Promyelocytic Leukaemia
Arsenic Tri-Oxide
 
Description Background: Acute promyelocytic leukaemia (APL) is curable with carefully selected treatment protocol. Reduction of early fatal haemorrhage in initial phase of induction with cost effective combination of chemotherapeutic agents is considered to be the main challenge for successful outcome in APL. Objective: The study was conducted to see the effectiveness of the use of all-trans retinoic acid (ATRA) followed by single agent Arsenic tri oxide (ATO) in the induction phase of the management of APL. Methodology: This is an observational study and was conducted from October 2012 to September 2013, in department of Haematology and BMT of Dhaka Medical College Hospital, Dhaka, Bangladesh. Total 17 patients with PML/RARA positive APL were enrolled and all patients were treated with sequential use of ATRA in a dose of 45mg/m2 for initial 2-3 weeks up to differentiation and then ATO in a dose of 0.15mg/kg daily was used in induction up to 60 days after taking informed written consent. Outcome was drawn after consolidation of therapy. Results: The morphologic complete remission rate was 88.2%. Remission failure was in observed in 2 cases (11.8%) that died at day 12 and day 51 due to differentiation syndrome and arrhythmia respectively. No death observed within first 10 days of treatment initiation. Complications observed during management were weight gain (11, 64.7%), hyper leucocytosis (10, 58.8%), ATRA syndrome (9, 52.9%), headache (6, 35.3%), tachycardia (5, 29.4%), hypomagnesaemia (3, 17.7%) and supra ventricular tachycardia (1, 5.8%).  Conclusion: Initial use of ATRA up to differentiation of promyelocytes before use of single agent ATO induction and consolidation can be a cost-effective alternative against newly diagnosed APL in reduction of early haemorrhagic death.
 
Publisher Haematology Society of Bangladesh
 
Date 2020-05-13
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer-Reviewed Article
 
Format text/html
application/pdf
 
Identifier https://journal.hematologybd.org/index.php/haematoljbd/article/view/10
10.37545/haematoljbd201810
 
Source Haematology Journal of Bangladesh; Vol. 2 No. 01 (2018); 3-7
2707-1405
2523-1219
 
Language eng
 
Relation https://journal.hematologybd.org/index.php/haematoljbd/article/view/10/91
https://journal.hematologybd.org/index.php/haematoljbd/article/view/10/92
 
Rights Copyright (c) 2018 AKM Mynul Islam, Mohammad Ali, Mohammad Abdullah Al Anis, Ahmad Monzurul Aziz, Syeda Subrina Siddika, Salina Haque, Zulfia Zinat Chowdhury, Akhil Ranjon Biswas, Tasneem Ara, Md. Mahabubur Rahman, Salma Afrose
https://creativecommons.org/licenses/by-nc/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library